AGEN vs FONR

AGEN's deterministic health scores are severely compromised: a Piotroski F-Score of 0/9 signals extreme financial distress, and the absence of an Altman Z-Score with negative profitability and liquidity ratios indicates high bankruptcy risk. Despite a 20.4% YoY revenue growth and recent EPS improvement, the company remains unprofitable with a -32.92% profit margin and negative ROA. The stock trades at a price/sales of 1.35, but with no intrinsic value or Graham Number, it lacks a fundamental floor. Analysts' target price of $12.33 is not supported by current fundamentals, suggesting overvaluation based on speculative growth expectations.

FONR presents as a classic value play with a stable Piotroski F-Score of 4/9 and a current price ($18.61) trading significantly below its Graham Number ($26.43). The company maintains an exceptionally strong balance sheet with a Current Ratio of 10.00 and very low debt (D/E 0.24), providing a massive safety cushion. However, this financial stability is offset by stagnant growth metrics, with YoY earnings growth of only 1.10%, and a bearish technical trend (10/100). Ultimately, the stock appears to be a low-risk, low-reward 'value trap' unless a growth catalyst emerges.